474 related articles for article (PubMed ID: 20018320)
1. Prospective randomized evaluation of periureteral botulinum toxin type A injection for ureteral stent pain reduction.
Gupta M; Patel T; Xavier K; Maruffo F; Lehman D; Walsh R; Landman J
J Urol; 2010 Feb; 183(2):598-602. PubMed ID: 20018320
[TBL] [Abstract][Full Text] [Related]
2. Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study.
Beddingfield R; Pedro RN; Hinck B; Kreidberg C; Feia K; Monga M
J Urol; 2009 Jan; 181(1):170-6. PubMed ID: 19013590
[TBL] [Abstract][Full Text] [Related]
3. A prospective, randomized, double-blinded placebo-controlled comparison of extended release oxybutynin versus phenazopyridine for the management of postoperative ureteral stent discomfort.
Norris RD; Sur RL; Springhart WP; Marguet CG; Mathias BJ; Pietrow PK; Albala DM; Preminger GM
Urology; 2008 May; 71(5):792-5. PubMed ID: 18339420
[TBL] [Abstract][Full Text] [Related]
4. Ureteral stents: morbidity and impact on quality of life.
Leibovici D; Cooper A; Lindner A; Ostrowsky R; Kleinmann J; Velikanov S; Cipele H; Goren E; Siegel YI
Isr Med Assoc J; 2005 Aug; 7(8):491-4. PubMed ID: 16106772
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
6. Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux.
Karsenty G; Elzayat E; Delapparent T; St-Denis B; Lemieux MC; Corcos J
J Urol; 2007 Mar; 177(3):1011-4. PubMed ID: 17296399
[TBL] [Abstract][Full Text] [Related]
7. A prospective randomized single-blind comparison of ureteral stents composed of firm and soft polymer.
Joshi HB; Chitale SV; Nagarajan M; Irving SO; Browning AJ; Biyani CS; Burgess NA
J Urol; 2005 Dec; 174(6):2303-6. PubMed ID: 16280829
[TBL] [Abstract][Full Text] [Related]
8. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder.
Haferkamp A; Schurch B; Reitz A; Krengel U; Grosse J; Kramer G; Schumacher S; Bastian PJ; Büttner R; Müller SC; Stöhrer M
Eur Urol; 2004 Dec; 46(6):784-91. PubMed ID: 15548448
[TBL] [Abstract][Full Text] [Related]
9. Botulinum toxin reduces anal spasm but has no effect on pain after haemorrhoidectomy.
Singh B; Box B; Lindsey I; George B; Mortensen N; Cunningham C
Colorectal Dis; 2009 Feb; 11(2):203-7. PubMed ID: 18462246
[TBL] [Abstract][Full Text] [Related]
10. A novel drug eluting ureteral stent: a prospective, randomized, multicenter clinical trial to evaluate the safety and effectiveness of a ketorolac loaded ureteral stent.
Krambeck AE; Walsh RS; Denstedt JD; Preminger GM; Li J; Evans JC; Lingeman JE;
J Urol; 2010 Mar; 183(3):1037-42. PubMed ID: 20092835
[TBL] [Abstract][Full Text] [Related]
11. What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection.
Khan S; Kessler TM; Apostolidis A; Kalsi V; Panicker J; Roosen A; Gonzales G; Haslam C; Elneil S; Fowler CJ; Dasgupta P
J Urol; 2009 Apr; 181(4):1773-8. PubMed ID: 19233414
[TBL] [Abstract][Full Text] [Related]
12. Stent positioning after ureteroscopy for urinary calculi: the question is still open.
Damiano R; Autorino R; Esposito C; Cantiello F; Sacco R; de Sio M; D'Armiento M
Eur Urol; 2004 Sep; 46(3):381-7; discussion 387-8. PubMed ID: 15306112
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the effects of ice application on patient comfort before and after botulinum toxin type A injections.
Saeliw P; Preechawai P; Aui-aree N
J Med Assoc Thai; 2010 Oct; 93(10):1200-4. PubMed ID: 20973324
[TBL] [Abstract][Full Text] [Related]
14. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity.
Rajkumar GN; Small DR; Mustafa AW; Conn G
BJU Int; 2005 Oct; 96(6):848-52. PubMed ID: 16153215
[TBL] [Abstract][Full Text] [Related]
15. Effects of tamsulosin on lower urinary tract symptoms due to double-J stent: a prospective study.
Wang CJ; Huang SW; Chang CH
Urol Int; 2009; 83(1):66-9. PubMed ID: 19641362
[TBL] [Abstract][Full Text] [Related]
16. Is ureteral stenting necessary after uncomplicated ureteroscopic lithotripsy? A prospective, randomized controlled trial.
Chen YT; Chen J; Wong WY; Yang SS; Hsieh CH; Wang CC
J Urol; 2002 May; 167(5):1977-80. PubMed ID: 11956421
[TBL] [Abstract][Full Text] [Related]
17. Role of ureteral stenting after uncomplicated ureteroscopy for distal ureteral stones: a randomized, controlled trial.
Ibrahim HM; Al-Kandari AM; Shaaban HS; Elshebini YH; Shokeir AA
J Urol; 2008 Sep; 180(3):961-5. PubMed ID: 18639269
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial.
Sahai A; Khan MS; Dasgupta P
J Urol; 2007 Jun; 177(6):2231-6. PubMed ID: 17509328
[TBL] [Abstract][Full Text] [Related]
19. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra.
Smith CP; Nishiguchi J; O'Leary M; Yoshimura N; Chancellor MB
Urology; 2005 Jan; 65(1):37-41. PubMed ID: 15667859
[TBL] [Abstract][Full Text] [Related]
20. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.
Schmid DM; Sauermann P; Werner M; Schuessler B; Blick N; Muentener M; Strebel RT; Perucchini D; Scheiner D; Schaer G; John H; Reitz A; Hauri D; Schurch B
J Urol; 2006 Jul; 176(1):177-85. PubMed ID: 16753396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
